These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 9354449

  • 1. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
    Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S.
    Cancer Res; 1997 Nov 01; 57(21):4855-61. PubMed ID: 9354449
    [Abstract] [Full Text] [Related]

  • 2. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
    Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V, Man S.
    Cancer Res; 2000 Jan 15; 60(2):365-71. PubMed ID: 10667589
    [Abstract] [Full Text] [Related]

  • 3. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC.
    Clin Cancer Res; 2003 Nov 01; 9(14):5205-13. PubMed ID: 14614000
    [Abstract] [Full Text] [Related]

  • 4. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes.
    Evans EM, Man S, Evans AS, Borysiewicz LK.
    Cancer Res; 1997 Jul 15; 57(14):2943-50. PubMed ID: 9230206
    [Abstract] [Full Text] [Related]

  • 5. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
    Valdespino V, Gorodezky C, Ortiz V, Kaufmann AM, Roman-Basaure E, Vazquez A, Berumen J.
    Gynecol Oncol; 2005 Jan 15; 96(1):92-102. PubMed ID: 15589586
    [Abstract] [Full Text] [Related]

  • 6. Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.
    Hara M, Matsueda S, Tamura M, Takedatsu H, Tanaka M, Kawano K, Mochizuki K, Kamura T, Itoh K, Harada M.
    Int J Oncol; 2005 Nov 15; 27(5):1371-9. PubMed ID: 16211234
    [Abstract] [Full Text] [Related]

  • 7. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL.
    Cancer Res; 2003 Sep 15; 63(18):6032-41. PubMed ID: 14522932
    [Abstract] [Full Text] [Related]

  • 8. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T, Pries F, Bungener L, Kraak M, Regts J, Wilschut J.
    Gene Ther; 2000 Nov 15; 7(21):1859-66. PubMed ID: 11110419
    [Abstract] [Full Text] [Related]

  • 9. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
    Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM.
    J Immunol; 1995 Jun 01; 154(11):5934-43. PubMed ID: 7538538
    [Abstract] [Full Text] [Related]

  • 10. [Detection of high-risk human papillomavirus (HPV) E6 and E7 oncogene transcripts increases the specificity of the detection of a cervical intraepithelial neoplasia (CIN)].
    Sotlar K, Diemer D, Stubner A, Menton S, Menton M, Dietz K, Wallwiener D, Bültmann B.
    Verh Dtsch Ges Pathol; 2005 Jun 01; 89():195-200. PubMed ID: 18035691
    [Abstract] [Full Text] [Related]

  • 11. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
    Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, van der Burg SH.
    Cancer Res; 2003 Feb 01; 63(3):636-41. PubMed ID: 12566307
    [Abstract] [Full Text] [Related]

  • 12. Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer.
    Schoell WM, Mirhashemi R, Liu B, Janicek MF, Podack ER, Penalver MA, Averette HE.
    Gynecol Oncol; 1999 Sep 01; 74(3):448-55. PubMed ID: 10479508
    [Abstract] [Full Text] [Related]

  • 13. Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens.
    Kaufmann AM, Gissmann L, Schreckenberger C, Qiao L.
    Cancer Gene Ther; 1997 Sep 01; 4(6):377-82. PubMed ID: 9408608
    [Abstract] [Full Text] [Related]

  • 14. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
    Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Jayaprabhu S, Pecorelli S, Parham GP, Cannon MJ.
    Clin Cancer Res; 2001 Mar 01; 7(3 Suppl):804s-810s. PubMed ID: 11300476
    [Abstract] [Full Text] [Related]

  • 15. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
    Daemen T, Riezebos-Brilman A, Regts J, Dontje B, van der Zee A, Wilschut J.
    Antivir Ther; 2004 Oct 01; 9(5):733-42. PubMed ID: 15535411
    [Abstract] [Full Text] [Related]

  • 16. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 17. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18.
    Castellanos MR, Hayes RL, Maiman MA.
    Gynecol Oncol; 2001 Jul 01; 82(1):77-83. PubMed ID: 11426965
    [Abstract] [Full Text] [Related]

  • 18. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
    Mizuuchi M, Hirohashi Y, Torigoe T, Kuroda T, Yasuda K, Shimizu Y, Saito T, Sato N.
    Exp Mol Pathol; 2012 Feb 01; 92(1):185-90. PubMed ID: 22032938
    [Abstract] [Full Text] [Related]

  • 19. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
    Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, Sette A, Trimble EL, Park RC, Marincola FM.
    Clin Cancer Res; 1998 Sep 01; 4(9):2103-9. PubMed ID: 9748126
    [Abstract] [Full Text] [Related]

  • 20. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
    Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki AB, Palefsky JM.
    J Infect Dis; 1997 Apr 01; 175(4):927-31. PubMed ID: 9086151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.